Author

A. Ribas

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 4 Cancer Biology· 2 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Organism:human· 6 Research Focus:cell type annotation· 5 Assay:proteomics· 3 Approach:statistical model· 3 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell-cell communication· 1

Frequent Co-Authors

A. Drakaki· 2 shared A. T. Hoang· 2 shared A. Y. Patel· 2 shared H.-C. Chen· 2 shared M. A. Su· 2 shared M. G. Lechner· 2 shared P. Famini· 2 shared T. E. Angell· 2 shared

Activity by Year

2019-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. Drakaki

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

Clonally-Expanded, Thyrotoxic Autoimmune Mediator CD8+ T cells Driven by IL21 Contribute to Checkpoint Inhibitor Thyroiditis

M. G. Lechner, Z. Zhou, A. T. Hoang, N. Huang, J. Ortega, L. N. Scott, H.-C. Chen, A. Y. Patel, R. Y. Tafti, K. Kim, W. Hugo, P. Famini, A. Drakaki, A. Ribas, T. E. Angell, M. A. Su

The paper identifies clonally expanded CD8+ T cells driven by IL21 in ICI-thyroiditis using scRNA-seq and validates their role in thyroid inflammation.

bioRxiv · Dec 18, 2022 · PreprintImmunology

Inhibition of the IL-17A axis Protects against Immune-related Adverse Events while Supporting Checkpoint Inhibitor Anti-tumor Efficacy

M. G. Lechner, A. Y. Patel, W. Hugo, T. E. Angell, M. I. Cheng, M. S. Pioso, A. T. Hoang, N. Yakobian, E. C. McCarthy, H.-C. Chen, E. D. Rodriguez, L. Guo, M. Astourian, A. Drakaki, P. Famini, , M. A. Su

This study shows that inhibiting the IL-17A axis reduces immune-related adverse events in checkpoint inhibitor-treated mice without affecting anti-tumor efficacy.

bioRxiv · Jan 19, 2022Immunology

Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response

A. Gangaev, E. A. Rozeman, M. W. Rohaan, D. Philips, S. Patiwael, J. H. van den Berg, A. Ribas, D. Schadendorf, B. Schilling, T. Shumacher, C. Blank, J. B. A. G. Haanen, P. Kvistborg

The paper shows PD-1 blockade in melanoma patients does not increase the breadth or magnitude of melanoma-reactive CD8 T cells in peripheral blood, suggesting PD-1 acts mainly at the tumor site.

bioRxiv · Dec 15, 2020Immunology

Autoantibody landscape of advanced prostate cancer

W. S. Chen, W. A. Haynes, R. Waitz, K. Kamath, A. Vega-Crespo, R. Shrestha, M. Zhang, A. Foye, I. Baselga Carretero, I. Garcilazo Perez, M. Zhang, S. G. Zhao, M. Sjostrom, D. A. Quigley, J. Chou, , F. Y. Feng

This study characterizes the autoantibody landscape in metastatic castration-resistant prostate cancer using serum epitope repertoire analysis and identifies novel tumor-specific epitopes.

bioRxiv · May 2, 2020 · PreprintCancer Biology

Prioritization of SARS-CoV-2 epitopes using a pan-HLA and global population inference approach

K. M. Campbell, G. Steiner, D. K. Wells, A. Ribas, A. Kalbasi

The paper predicts SARS-CoV-2 peptide-HLA complexes across global populations and prioritizes epitopes for specific groups.

bioRxiv · Mar 30, 2020 · PreprintImmunology

Defective Nucleotide Catabolism Defines a Subset of Cancers Sensitive to Purine Nucleoside Phosphorylase Inhibition

E. R. Abt, V. Lok, T. M. Le, S. Poddar, W. Kim, J. R. Capri, G. Abril-Rodriguez, T. R. Donahue, J. Czernin, T. Mehrling, A. Ribas, C. G. Radu

This study identifies SAMHD1, dCK, and CDA as biomarkers for predicting sensitivity to PNP inhibitors in cancers, showing that PNP inhibition can target both hematological and solid tumors.

bioRxiv · Nov 4, 2019 · PreprintCancer Biology

Trajectories from Snapshots: Integrated proteomic and metabolic single-cell assays reveal multiple independent adaptive responses to drug tolerance in a BRAF-mutant melanoma cell line

Y. Su, G. Li, M. E. Ko, H. Cheng, R. Zhu, M. Xue, J. Wang, J. W. Lee, L. Frankiw, A. Xu, S. Wong, L. Robert, K. Takata, S. Huang, A. Ribas, , J. R. Heath

The paper uses integrated proteomic and metabolic single-cell assays to identify two distinct adaptive pathways in BRAF-mutant melanoma cells during drug treatment.

bioRxiv · Sep 12, 2019 · PreprintBioengineering